--- title: "Inflammatory Bowel Disease QUOTIENT | Sutter Health" description: "Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission" url: "https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Inflammatory Bowel Disease QUOTIENT # Inflammatory Bowel Disease QUOTIENT **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT05230173). #### Locations - Sunnyvale - Palo Alto #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). This is a pragmatic, open-label, multicenter randomized control trial (RCT) conducted in asymptomatic patients with IBD who have persistent moderate to severe endoscopic inflammation despite optimization of index TIM. This study plans to recruit approximately 250 participants in the United States, who will either switching to treatment with alternative TIM to treat to a target of endoscopic remission or continue index optimized TIM. After randomization, patients will be followed prospectively within routine clinical practice over 2 years (104 weeks). ![Ryan A McConnell, M.D.](https://dyn.mktgcdn.com/p/LAIgIdYkiJk-DXnAW0o98yR3oSpGumxcc1pavHU7STQ/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Ryan A McConnell, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/ryan-a-mcconnell-md-1078064874) ## Funder University of California, San Diego ## Email us to enroll - [Email Sunnyvale](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Inflammatory%20Bowel%20Disease%20QUOTIENT%20in%20Sunnyvale&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Palo Alto](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Inflammatory%20Bowel%20Disease%20QUOTIENT%20in%20Palo%20Alto&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Ulcerative Colitis XmAb942-01](https://www.sutterhealth.org/research/clinical-trials/ulcerative-colitis-xmab942-01-2064309878) A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis. XmAb942-01 **Status:** Open to Enrollment - Clinical trial ### [Inflammatory Bowel Disease BOOM-IBD2](https://www.sutterhealth.org/research/clinical-trials/inflammatory-bowel-disease-boom-ibd2-2007479061) BOOM-IBD2 Clinical Trial to Evaluate the Effectiveness of Sacral Neuromodulation for the Treatment of Inflammatory Bowel Disease (IBD). **Status:** Open to Enrollment - Clinical trial ### [Stress Urinary Incontinence PAS001 ProACT](https://www.sutterhealth.org/research/clinical-trials/stress-urinary-incontinence-pas001-proact-2080051902) Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men **Status:** Open to Enrollment - Clinical trial ### [Chronic Nausea and Vomiting NAVIGATE](https://www.sutterhealth.org/research/clinical-trials/chronic-nausea-and-vomiting-navigate-2023207930) A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System **Status:** Open to Enrollment - Clinical trial ### [Gastroparesis EXPEDITE](https://www.sutterhealth.org/research/clinical-trials/gastroparesis-expedite-2007479109) Examination of Programming with the Enterra® Therapy System (EXPEDITE) in a Double-Blinded, Randomized, Prospective Study in the Treatment of Nausea and Vomiting Symptoms Using Gastric Electrical Stimulation **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Inflammatory Bowel Disease QUOTIENT"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942#medicalwebpage","name":"Inflammatory Bowel Disease QUOTIENT","description":"Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission","url":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942","inLanguage":"en-US","dateModified":"2026-06-08","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942#breadcrumblist"},"mentions":[{"@type":"Person","name":"Ryan A McConnell, M.D.","url":"https://www.sutterhealth.org/research/investigators/ryan-a-mcconnell-md-1078064874","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942#medicaltrial","name":"Inflammatory Bowel Disease QUOTIENT","alternateName":"Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission","url":"https://www.sutterhealth.org/research/clinical-trials/quotient-1049141942","description":"This is a pragmatic, open-label, multicenter randomized control trial (RCT) conducted in asymptomatic patients with IBD who have persistent moderate to severe endoscopic inflammation despite optimization of index TIM. This study plans to recruit approximately 250 participants in the United States, who will either switching to treatment with alternative TIM to treat to a target of endoscopic remission or continue index optimized TIM. After randomization, patients will be followed prospectively within routine clinical practice over 2 years (104 weeks).","identifier":"NCT05230173","code":{"@type":"MedicalCode","codeValue":"NCT05230173","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT05230173","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Crohn's Disease"},{"@type":"MedicalCondition","name":"Ulcerative Colitis"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sunnyvale"},{"@type":"AdministrativeArea","name":"Palo Alto"}]} ```